Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

(2011) Jürgen K. Rockstroh et al.   AIDS

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

(2011) Calvin Cohen et al.   AIDS

Switching between raltegravir resistance pathways analyzed by deep sequencing

(2011) Rithun Mukherjee et al.   AIDS

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

(2011) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors

(2011) Bluma G. Brenner et al.   JOURNAL OF MEDICAL VIROLOGY

The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains

(2011) Jean L Mbisa et al.   Retrovirology

Absence of Primary Integrase Resistance Mutations in HIV Type 1-Infected Patients in Venezuela

(2010) Héctor R. Rangel et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir

(2010) Vici Varghese et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

(2010) Jia Liu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure

(2010) Francisco M. Codoñer et al.   ANTIVIRAL RESEARCH

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption

(2010) F. Canducci et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness

(2010) Zixin Hu et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

(2010) D. da Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir

(2010) Filippo Canducci et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations

(2010) Michael R. Jordan et al.   JOURNAL OF VIROLOGICAL METHODS

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

(2010) Sandrine Reigadas et al.   PLoS One

Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing

(2010) Charlotte Hedskog et al.   PLoS One

Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy

(2010) Binshan Shi et al.   VIROLOGY

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

(2009) Filippo Canducci et al.   AIDS

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy

(2009) Ruth Bridget Ferns et al.   AIDS

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates

(2009) Maria José Buzón et al.   AIDS

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

(2009) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes

(2009) Birgitte B. Simen et al.   JOURNAL OF INFECTIOUS DISEASES

Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens

(2009) Fausto Baldanti et al.   JOURNAL OF MEDICAL VIROLOGY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Analysis of Nevirapine Resistance Mutations in Cloned HIV Type 1 Variants from HIV-Infected Ugandan Infants Using a Single-Step Amplification-Sequencing Method (AmpliSeq)

(2008) William Ian Towler et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing

(2008) J. F. Salazar-Gonzalez et al.   JOURNAL OF VIROLOGY